百克生物：三价流感病毒裂解疫苗（BK-01 佐剂）临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine (BK-01 adjuvant), targeting the prevention of influenza caused by specific virus strains in individuals aged 60 and above [1] Group 1 - The vaccine is designed to stimulate a stronger immune response in the target population [1] - The approval allows the company to proceed with clinical trials, which is a significant step in the vaccine development process [1]